
Lexeo Therapeutics to host event on clinical measures in PKP2 arrhythmogenic cardiomyopathy
Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...





